NDAINJECTIONINJECTABLE
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Diatrizoate meglumine is a high-osmolarity contrast medium administered via injection for radiographic imaging procedures. It is used to visualize internal body structures during X-ray and fluoroscopy examinations, particularly for cardiac, urinary, and gastrointestinal imaging. The drug works by absorbing X-rays, creating contrast between tissues to enhance diagnostic image quality.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30%) signals potential team contraction or repositioning toward lower-volume niche diagnostic applications.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on diatrizoate meglumine offers limited career growth potential given its mature lifecycle, approaching LOE, and zero linked job openings. Roles are primarily focused on cost management, compliance, and operational efficiency rather than innovation or market expansion.
Diagnostic Imaging SpecialistRegulatory Affairs Specialist
Worked on DIATRIZOATE MEGLUMINE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.